We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Ardelyx (ARDX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.02 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $117.57 million, representing a year-over-year increase of 1.2%.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 50% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Ardelyx metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Product sales, net' will reach $114.14 million. The estimate indicates a change of +2.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Product sales- IBSRELA' will likely reach $85.75 million. The estimate indicates a change of +59.3% from the prior-year quarter.
It is projected by analysts that the 'Product sales- XPHOZAH' will reach $28.39 million. The estimate indicates a change of -50.3% from the prior-year quarter.
Shares of Ardelyx have experienced a change of +1.8% in the past month compared to the -1.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ARDX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key Metrics
In its upcoming report, Ardelyx (ARDX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.02 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $117.57 million, representing a year-over-year increase of 1.2%.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 50% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Ardelyx metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Product sales, net' will reach $114.14 million. The estimate indicates a change of +2.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Product sales- IBSRELA' will likely reach $85.75 million. The estimate indicates a change of +59.3% from the prior-year quarter.
It is projected by analysts that the 'Product sales- XPHOZAH' will reach $28.39 million. The estimate indicates a change of -50.3% from the prior-year quarter.
View all Key Company Metrics for Ardelyx here>>>Shares of Ardelyx have experienced a change of +1.8% in the past month compared to the -1.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ARDX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .